NCT00276003View on ClinicalTrials.gov

INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

June 30, 2005

Study Completion Date

August 31, 2005

Conditions
Non-Hodgkin's LymphomaCancer
Interventions
DRUG

Gemcitabine, Irinotecan, Allopurinol.

Gemcitabine - 1000mg/m2; IV; d1, 8; q 21 days Irinotecan - 100mg/m2; IV; d1, 8; q 21 days Allopurinol - 300 mg; PO; day 1-5; 1st cycle

Trial Locations (2)

87108

Lovelace Sandia Health Systems Dept of Hematology, Albuquerque

87131

University of New Mexico, Albuquerque

All Listed Sponsors
lead

University of New Mexico

OTHER

NCT00276003 - INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma. | Biotech Hunter | Biotech Hunter